{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:47:54Z","timestamp":1790005674055,"version":"4.0.1"},"reference-count":33,"publisher":"Cambridge University Press (CUP)","issue":"S12","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3232,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2006]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Response and remission rates are commonly used to evaluate the efficacy of treatments for anxiety disorders and other psychiatric illnesses. Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning. Response and remission are often defined using psychiatric rating scales, based on score cutoffs or the magnitude of score changes from baseline. While no universally accepted criteria exist, a commonly used threshold for response is a\n                    <jats:underline>&gt;<\/jats:underline>\n                    50% improvement in the total score, while for remission, various cutoff points have been used. Comparison of cutoffs or change scores for disease-specific scales with Clinical Global Impressions ratings is a useful way of evaluating response and remission criteria across disorders. To illustrate the use of disease-specific and global measures, this article summarizes data from randomized, placebo-controlled studies of adult patients with generalized anxiety disorder, social anxiety disorder, or panic disorder treated with the serotonin norepinephrine reuptake inhibitor venlafaxine extended release, for which acute-phase data are available (a total of 13 trials).\n                  <\/jats:p>","DOI":"10.1017\/s1092852900025815","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:52:05Z","timestamp":1470099125000},"page":"21-28","source":"Crossref","is-referenced-by-count":43,"title":["Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach"],"prefix":"10.1017","volume":"11","author":[{"given":"Borwin","family":"Bandelow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900025815_ref033","doi-asserted-by":"publisher","DOI":"10.1002\/da.20149"},{"key":"S1092852900025815_ref032","first-page":"4","article-title":"The road to recovery in panic disorder: response, remission, and relapse","volume":"59","author":"Shear","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852900025815_ref031","volume-title":"Depress Anxiety","author":"Bandelow","year":"2006"},{"key":"S1092852900025815_ref030","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"S1092852900025815_ref029","first-page":"5","article-title":"Treatment of anxiety disorders to remission","volume":"62","author":"Ballenger","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"S1092852900025815_ref028","volume-title":"Depress Anxiety","author":"Pollack","year":"2006"},{"key":"S1092852900025815_ref025","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.4.352"},{"key":"S1092852900025815_ref024","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000138764.31106.60"},{"key":"S1092852900025815_ref022","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.2.190"},{"key":"S1092852900025815_ref021","doi-asserted-by":"publisher","DOI":"10.1002\/hup.602"},{"key":"S1092852900025815_ref019","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(03)00046-4"},{"key":"S1092852900025815_ref020","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.968"},{"key":"S1092852900025815_ref016","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.15"},{"key":"S1092852900025815_ref015","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000154840.63529.5d"},{"key":"S1092852900025815_ref014","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.749"},{"key":"S1092852900025815_ref013","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000084025.22282.84"},{"key":"S1092852900025815_ref012","first-page":"40","article-title":"Establishment of remission criteria for anxiety disorders","volume":"64","author":"Doyle","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"S1092852900025815_ref011","first-page":"29","article-title":"Clinical guidelines for establishing remission in patients with depression and anxiety","volume":"60","author":"Ballenger","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S1092852900025815_ref010","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.59.1.12"},{"key":"S1092852900025815_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"S1092852900025815_ref007","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"S1092852900025815_ref005","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.11.1571"},{"key":"S1092852900025815_ref004","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199506000-00003"},{"key":"S1092852900025815_ref003","doi-asserted-by":"publisher","DOI":"10.1159\/000414022"},{"key":"S1092852900025815_ref002","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S1092852900025815_ref001","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S1092852900025815_ref017","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0805"},{"key":"S1092852900025815_ref018","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"S1092852900025815_ref006","unstructured":"European Medicines Agency Committee for Medical Products for Human Use: Guideline on clinical investigation of medical products indicated for the treatment of panic disorder. Available at: http:\/\/www.emea.eu.int\/pdfs\/human\/ewp\/428002.en.pdf. Accessed August 17, 2006."},{"key":"S1092852900025815_ref026","volume-title":"Venlafaxine XR versus placebo in the short-term treatment of panic disorder","author":"Liebowitz","year":"2004"},{"key":"S1092852900025815_ref023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0213"},{"key":"S1092852900025815_ref027","volume-title":"Short-term treatment of panic disorder: venlafaxine XR vs paroxetine or placebo","author":"Pollack","year":"2005"},{"key":"S1092852900025815_ref009","volume-title":"Measurements of Patients' Discomfort, Distress and Disability: Users' Guide to the Medical Literature","author":"Furukawa","year":"2006"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900025815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T15:09:57Z","timestamp":1556896197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900025815\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":33,"journal-issue":{"issue":"S12","published-print":{"date-parts":[[2006]]}},"alternative-id":["S1092852900025815"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900025815","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}